Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Leveraging WeChat Social-Media and Messaging Platform to Increase Physical Activity in Chinese Glaucoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03567226
Recruitment Status : Completed
First Posted : June 25, 2018
Last Update Posted : January 15, 2019
Sponsor:
Collaborator:
Wenzhou Medical University
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The positive effects of exercise on ocular health are known, but modern lifestyles have made it difficult to incorporate physical activity into the daily lives of the Chinese population. Recent studies suggest that exercise plays an important role in lowering intraocular pressure (IOP) by protecting retinal ganglion cells (RGCs) in glaucoma patients as well as other potential neuroprotective benefits. Increasing the amount of physical activity within the Chinese glaucoma population may have marked effects on health outcomes and coincides with the Chinese government's efforts to make exercise an urgent public health priority. There is a need for innovative, cost-effective, and proven interventions to promote exercise behavior change and social media platforms may be able to fill this niche. WeChat is China's largest and most frequently used social media and messaging application with an estimated 570 million users. The platform has been found to be a useful tool in healthcare settings to promote weight-loss, health literacy, and patient adherence in Chinese populations. This study is a 5-weeks randomized control trial with three total study visits. 80 patients from an academic glaucoma clinic in Wenzhou Medical College will be randomized into two groups. The intervention group will be enrolled into an Official WeChat Group and receive periodic reminders to exercise, health education materials, and motivational incentives. The control group will receive weekly reminders and leaflets at the first clinic visit. Patients' daily step data will be monitored using an Accelerometer WGT3X-BT. The intervention duration will include an initial clinic visit, a one-week follow-up after wearing the accelerometer, and then a subsequent one-month follow-up visit after wearing the accelerometer. At the one-week visit the patient will be randomized and at the subsequent one-month visit there will be a close-out discussion about the study. In addition to collecting step data at clinic visits, investigators will also measure patients' visual field tests, optical coherence tomography angiography (angio-OCT), and intraocular pressure (IOP) using Goldmann Tonometry. The investigators' hypothesis is that using an Official WeChat Patient Group will be a robust and effective stimulus to increase physical exercise.

Condition or disease Intervention/treatment Phase
Glaucoma Behavioral: WeChat Group Behavioral: Counselling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Leveraging WeChat Social-Media and Messaging Platform to Increase Physical Activity in Chinese Glaucoma Patients: A Pilot Study
Actual Study Start Date : June 25, 2018
Actual Primary Completion Date : November 26, 2018
Actual Study Completion Date : November 26, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention Group
The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
Behavioral: WeChat Group

Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:

  1. Daily/Weekly Reminders to exercise
  2. Health education materials regarding glaucoma and general health and exercise
  3. Motivational content
  4. Surveys to gauge what information participants found most interesting and useful to help them exercise

Active Comparator: Control Group
Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
Behavioral: Counselling
Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit




Primary Outcome Measures :
  1. Efficacy of using WeChat as an intervention to increase physical activity in Chinese glaucoma patients [ Time Frame: 5 weeks ]

    The primary outcome variable will be the number of daily steps taken over the course of one month for each participant. This outcome will be measured by having participants wear the Accelerometer WGT3X-BT, from which we can collect steps data. From this primary outcome measure we will also assess the change in number of steps taken comparing the first week to the following month after the intervention.

    Assuming mean enrollment number of steps per day is 9,302.29, we can detect an average increase of 2,500 steps per day with alpha set to 0.05 with 80% power.



Secondary Outcome Measures :
  1. Time spent in moderate to vigorous physical activity [ Time Frame: 5 weeks ]
    We will also analyze the time spent in moderate to vigorous physical activity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glaucoma diagnosis
  • Age 40 years and above
  • Ability to sign informed consent
  • Ability to use WeChat

Exclusion Criteria:

  • Patients with severe heart, lung, or kidney disease which may prevent them from exercising
  • Patients who self-report walking 12,000 steps or more per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567226


Locations
Layout table for location information
China, Zhejiang
The affiliated eye hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Sponsors and Collaborators
Johns Hopkins University
Wenzhou Medical University
Investigators
Layout table for investigator information
Principal Investigator: David Friedman, MD, MPH, PhD Johns Hopkins University
Principal Investigator: Yuanbo Liang, MD, PhD Clinical & Epidemiological Eye Research Centre, The affiliated eye hospital of Wenzhou Medical University

Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT03567226     History of Changes
Other Study ID Numbers: IRB00172315
First Posted: June 25, 2018    Key Record Dates
Last Update Posted: January 15, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Ocular Hypertension
Eye Diseases